Healthcare · Pharmaceuticals & Biotechnology
QVM read Mixed signals Quality Weak, Valuation Fairly Valued, Momentum Neutral
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Panacea Biotec is a global generic and specialty pharmaceutical and vaccine maker. It has principal offices in New Delhi, Mumbai, and Lalru. It has business interests in research, development, manufacturing and marketing of pharmaceutical formulations, vaccines, biosimilars, and natural products.
Source: Wikipedia
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).
Ranks #79 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 3 Oct 2025 | Nosheen Sheikh | Immediate relative | Buy | 0 | ₹0 |
| 2 Jan 2025 | Sandeep Jain | Promoter | Sell | 0 | ₹0 |
| 31 Dec 2024 | Sandeep Jain | Promoter | Sell | 0 | ₹0 |
| 30 Dec 2024 | Rajesh Jain | Director | Buy | 0 | ₹0 |
| 25 Dec 2024 | Sandeep Jain | Promoter | Sell | 0 | ₹0 |
| 25 Dec 2024 | Sandeep Jain | Promoter | Sell | 0 | ₹0 |
| 20 Dec 2024 | Sandeep Jain | Promoter | Sell | 0 | ₹0 |
| 20 Dec 2024 | Sandeep Jain | Promoter | Sell | 0 | ₹0 |
| 17 Dec 2024 | Sandeep Jain | Promoter | Sell | 0 | ₹0 |
| 17 Dec 2024 | Sandeep Jain | Promoter | Sell | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 9 Jun 2026 | QE SECURITIES LLP | Bulk | Sell | 400,548 | 621.4900 | NSE |
| 9 Jun 2026 | QE SECURITIES LLP | Bulk | Buy | 402,366 | 621.9900 | NSE |
| 9 Jun 2026 | NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Sell | 531,543 | 624.6600 | NSE |
| 9 Jun 2026 | NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Buy | 531,543 | 624.4600 | NSE |
| 9 Jun 2026 | MICROCURVES TRADING PRIVATE LIMITED | Bulk | Buy | 965,723 | 626.4200 | NSE |
| 9 Jun 2026 | MICROCURVES TRADING PRIVATE LIMITED | Bulk | Sell | 965,723 | 626.6100 | NSE |
| 9 Jun 2026 | JUNOMONETA FINSOL PRIVATE LIMITED | Bulk | Buy | 566,807 | 623.6000 | NSE |
| 9 Jun 2026 | JUNOMONETA FINSOL PRIVATE LIMITED | Bulk | Sell | 565,285 | 624.0000 | NSE |
| 9 Jun 2026 | JUMP TRADING FINANCIAL INDIA PRIVATE LIMITED | Bulk | Sell | 380,507 | 626.1200 | NSE |
| 9 Jun 2026 | JUMP TRADING FINANCIAL INDIA PRIVATE LIMITED | Bulk | Buy | 380,507 | 624.6700 | NSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 19 Sep 2011 | Annual General Meeting And Dividend Re.0.75 Per Share | 0.7500 | — |
| 16 Sep 2010 | Annual General Meeting And Dividend Re.0.25 Per Share | 0.2500 | — |
| 19 Sep 2008 | Agm/Dividend - 100% | — | — |
| 21 Sep 2007 | Agm/Dividend-100% | — | — |
| 22 Sep 2006 | Agm/Dividend-100% | — | — |
| 12 Aug 2005 | Agm/Dividend @ 150% | — | — |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| 19 Sep 2024 | OTHER | Annual General Meeting |
| 21 Sep 2023 | OTHER | Annual General Meeting |
| 19 Sep 2022 | OTHER | Annual General Meeting |
| 16 Sep 2021 | OTHER | Annual General Meeting |
| 15 Dec 2020 | OTHER | Annual General Meeting |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 13 Aug 2026 | Financial Results | Yes |
| 30 May 2026 | Financial Results/Dividend | Yes |
| 29 May 2026 | Financial Results/Dividend | Yes |
| 11 Feb 2026 | Financial Results | Yes |
| 14 Nov 2025 | Financial Results | Yes |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 1 Oct 2026 | AGM/EGM | Panacea Biotec Ltd - 531349 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report |
| 1 Oct 2026 | AGM/EGM | Panacea Biotec Ltd - 531349 - Shareholder Meeting / Postal Ballot-Outcome of AGM |
| 1 Oct 2026 | Shareholders meeting | Panacea Biotec Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 29, 2026. Further, the company has informed the Exchange regarding voting results. |
| 29 Sep 2026 | AGM/EGM | Panacea Biotec Ltd - 531349 - Shareholder Meeting / Postal Ballot-Outcome of AGM |
| 29 Sep 2026 | Shareholders meeting | Panacea Biotec Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 29, 2026 |
| 29 Sep 2026 | Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company | Panacea Biotec Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company |
| 29 Sep 2026 | Company Update | Panacea Biotec Ltd - 531349 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI LODR Regulations') |
| 26 Sep 2026 | Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company | Panacea Biotec Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company |
| 26 Sep 2026 | Trading Window | Panacea Biotec Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 15 Sep 2026 | Company Update | Panacea Biotec Ltd - 531349 - Communication Sent To Physical Shareholders To Furnish PAN And KYC Details |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
